Article information
This is a review of the articles dealing with basic science published in recent issues of Archivos de Bronconeumología. Of particular interest with regard to chronic obstructive pulmonary disease were an article on extrapulmonary inflammation and oxidative stress and another on bronchial remodeling. The articles relating to asthma included a review on the use of drugs that block free immunoglobulin-E and an article about the contribution of experimental models to our knowledge of this disease. Two of the most interesting articles on the topic of lung cancer dealt with gene therapy and resistance to chemotherapy. Also notable were 2 studies that investigated ischemia-reperfusion injury. One evaluated tissue resistance to injury while the other analyzed the role played by interleukin-8 in this process. On the topic of pulmonary fibrosis, an article focused on potential biomarkers of progression and prognosis; others dealt with the contribution of experimental models to our understanding of this disorder and the fibrogenic role of transforming growth factor [.beta]. In the context of both sleep apnea syndrome and pulmonary infection, studies investigating the role of oxidative stress were published. Finally, 2 studies analyzed the diagnosis and treatment of tuberculosis and other pulmonary infections.
Key words:
Experimental models
Basic research
Molecular biology
Respiratory diseases
Se han revisado los artículos relacionados con las ciencias básicas que se han publicado recientemente en ARCHIVOS DE BRONCONEUMOLOGÍA. Respecto de la enfermedad pulmonar obstructiva crónica, destacan los relacionados con el estrés oxidativo y la inflamación extrapulmonar, y un estudio sobre la remodelación bronquial. Los artículos acerca del asma se centraron en revisiones sobre el uso de fármacos que bloquean la inmunoglobulina E libre y sobre las aportaciones de los modelos experimentales de la enfermedad. Respecto del cáncer de pulmón, cabe mencionar 2 trabajos centrados en la genoterapia y las resistencias ante la quimioterapia. También destacan 2 estudios sobre la lesión por isquemia-reperfusión, que valoraron el tiempo de resistencia tisular ante esta noxa y el papel de la interleucina-8. En el campo de la fibrosis pulmonar se revisaron los potenciales biomarcadores de progresión y pronóstico, así como el papel de los modelos experimentales de la enfermedad, publicándose además un trabajo sobre el papel fibrogénico del factor transformador de crecimiento beta. Sobre el síndrome de apneas del sueño y las infecciones pulmonares se publicaron sendos estudios acerca del papel del estrés oxidativo. Finalmente, 2 trabajos de investigación analizaron el diagnóstico y tratamiento de la tuberculosis y otras infecciones pulmonares.
Palabras clave:
Modelos experimentales
Investigación básica
Biología molecular
Enfermedades respiratorias
Full text is only aviable in PDF
References
[1]
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO working meeting. Available from: www.goldcopd.com
[2]
BR Celli, W MacNee, committee members.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[3]
American Thoracic Society.
Skeletal muscle dysfunction in chronic obstructive pulmonary disease: a statement of the American Thoracic Society and European Respiratory Society.
Am J Respir Crit Care Med, 159 (1999), pp. S1-S40
[4]
E Swallow, D Reyes, N Hopkinson, W Man, R Porcher, E Cetti, et al.
Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease.
Thorax, 62 (2007), pp. 115-120
[5]
J Gea, E Barreiro, M Orozco-Levi.
Skeletal muscle adaptation to disease states.
Skeletal muscle plasticity in health and disease: from genes to whole muscle, pp. 315-360
[6]
M Morlà, A Iglesias, J Sauleda, B Cosio, A Agustí, X Busquets.
Disminución de la expresión de la bomba de calcio sarcoplásmica (SERCA2) en el músculo esquelético de pacientes con EPOC y bajo peso corporal.
Arch Bronconeumol, 43 (2007), pp. 4-8
[7]
J Gea, E Barreiro, M Orozco-Levi.
Free radicals, cytokines and respiratory muscles in COPD patients.
Clin Pulm Med, 14 (2007), pp. 117-126
[8]
JL Izquierdo, C Almonacid, T Parra, J Pérez.
Inflamación pulmonar y sistémica en 2 fenotipos de EPOC.
Arch Bronconeumol, 42 (2006), pp. 332-337
[9]
G Peces-Barba, JA Barberà, A Agustí, C Casanova, A Casas, JL Izquierdo, et al.
Diagnóstico y manejo de la enfermedad pulmonar obstructiva crónica: guía conjunta de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Latinoamericana del Tórax (ALAT).
Arch Bronconeumol, 44 (2008), pp. 271-281
[10]
B Avilés, J Belda, G Margarit, J Bellido-Casado, C Martínez-Bru, P Casán.
Marcadores de remodelado bronquial en el esputo inducido de fumadores sanos.
Arch Bronconeumol, 42 (2006), pp. 235-240
[11]
G Margarit, J Belda, P Casan, J Sanchis.
Método para amplificar cultivos primarios de células epiteliales bronquiales.
Arch Bronconeumol, 41 (2005), pp. 524-527
[12]
J Belda, G Margarit, C Martínez, P Casan, F Rodríguez-Jerez, M Brufal, et al.
Exudado bronquial de proteínas séricas en las crisis de asma.
Arch Bronconeumol, 41 (2005), pp. 328-333
[13]
JJ Atkinson, RM Señor.
Matrix metalloproteinase-9 in lung remodeling.
Am J Respir Cell Mol Biol, 28 (2003), pp. 12-24
[14]
AM Vignola, L Riccobono, A Mirabella, M Profita, P Chánez, V Bellia, et al.
Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis.
Am J Respir Crit Care Med, 158 (1998), pp. 1945-1950
[15]
P Cabrera-Navarro, JC Rodríguez-Gallego.
Perfil farmacológico de omalizumab.
Arch Bronconeumol, 42 (2006), pp. 26-31
[16]
P Cabrera-Navarro.
Antiinmunoglobulina E, un anticuerpo monoclonal, en el tratamiento de las enfermedades respiratorias.
Arch Bronconeumol, 42 (2006), pp. 241-245
[17]
P Cabrera-Navarro.
Uso terapéutico de los anticuerpos monoclonales en neumología.
Arch Bronconeumol, 42 (2006), pp. 2-11
[19]
LA Beck, GV Marcotte, D MacGlashan, A Togias, S Saini.
Omalizumab-induced reductions in mast cell Fce epsilon RI expression and function.
J Allergy Clin Immunol, 114 (2004), pp. 527-530
[20]
R Djukanoviç, SJ Wilson, M Kraft, NN Jarjour, M Steel, KF Chung, et al.
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Am J Respir Crit Care Med, 170 (2004), pp. 583-593
[21]
D Ramos-Barbón.
Investigación básica sobre asma: ¿hacia dónde nos dirigimos?.
Arch Bronconeumol, 42 (2006), pp. 613-615
[22]
D Ramos-Barbón.
¿Podemos modificar el remodelado bronquial en el asma?.
Arch Bronconeumol, 41 (2005), pp. 3-9
[23]
J Cortijo.
Modelos experimentales de asma. Aportaciones y limitaciones.
Arch Bronconeumol, 39 (2003), pp. 54-56
[24]
P Boyle, S Gandini, N Gray.
Epidemiology of lung cancer: a century of great success and ignominious failure.
Textbook of lung cancer, pp. 13-25
[25]
S Dubey, CA Powell.
Update in lung cancer 2007.
Am J Respir Crit Care Med, 177 (2008), pp. 941-946
[26]
WT Beck, WS Dalton.
Mechanisms of drug resistance.
Cancer principles and practice of oncology, 6th ed., pp. 498-512
[27]
P Borst, R Evers, M Kool, J Wijnholds.
A family of drug transporters: the multidrug resistance-associated proteins.
J Natl Cancer Inst, 92 (2000), pp. 1295-1302
[28]
A Paredes, C Blanco, M Echenique, C Lobo.
Expresión de proteínas relacionadas con resistencia a múltiples fármacos y resistencia a la quimioterapia en el cáncer de pulmón.
Arch Bronconeumol, 43 (2007), pp. 479-484
[29]
M Rodrigo-Garzón, I Tirapu, A Arina, MN Centelles, J Zulueta.
Aplicación de tratamiento génico a un modelo subcutáneo de cáncer de pulmón murino.
Arch Bronconeumol, 42 (2006), pp. 526-532
[30]
LM Seijo, G Bastarrika, MD Lozano, JJ Zulueta.
Experiencia preliminar en el uso de la navegación electromagnética para el diagnóstico de nódulos pulmonares periféricos y adenopatías mediastínicas.
Arch Bronconeumol, 43 (2007), pp. 460-463
[31]
L Seijo, A Campo, AB Alcaide, MM Lacunza, AC Armendáriz, JJ Zulueta.
Manejo ambulatorio del derrame pleural maligno mediante colocación de un catéter de drenaje tunelizado. Experiencia preliminar.
Arch Bronconeumol, 42 (2006), pp. 660-662
[32]
MM Galagudza, IO Blokhin, AA Shmonin, KA Mischenko.
Reduction of myocardial ischemia-reperfusion injury with pre-and postconditioning: molecular mechanisms and therapeutic targets.
Cardiovasc Hematol Disord Drug Targets, 8 (2008), pp. 47-65
[33]
M Castellanos, T Sobrino, J Castillo.
Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra.
Cerebrovasc Dis, 21 (2006), pp. 71-79
[34]
AV Ovechkin, D Lominadze, KC Sedoris, TW Robinson, SC Tyagi, AM Roberts.
Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions.
Arch Physiol Biochem, 113 (2007), pp. 1-12
[35]
G Thabut, H Mal, J Cerrina, P Dartevelle, C Dromer, JF Velly, et al.
Graft ischemic time and outcome of lung transplantation: a multicenter analysis.
Am J Respir Crit Care Med, 171 (2005), pp. 786-791
[36]
RJ Novick, LE Bennett, DM Meyer, JD Hosenpud.
Influence of graft ischemic time and donor age on survival after lung transplantation.
J Heart Lung Transplant, 18 (1999), pp. 425-431
[37]
N Santana-Rodríguez, JL Martín, MA Ponce, A López, JA Ruiz, A Torres, et al.
Valoración de la lesión de isquemia-reperfusión y del rechazo agudo precoz en el trasplante pulmonar experimental con tiempo de isquemia prolongado.
Arch Bronconeumol, 43 (2007), pp. 373-377
[38]
JM Matilla, M García, M Sánchez, MJ Gayoso, F Heras, M Jiménez, et al.
Estudio de la expresión de interleucina-8 en el tejido pulmonar durante la isquemia-reperfusión.
Arch Bronconeumol, 43 (2007), pp. 542-548
[39]
H Mal, M Dehoux, C Sleiman, J Boczkowski, G Lesèche, R Pariente, et al.
Early release of proinflammatory cytokines after lung transplantation.
Chest, 113 (1998), pp. 645-651
[40]
JM Schröder, U Mrowietz, E Christophers.
Purification and partial biologic characterization of a human lymphocyte-derived peptide with potent neutrophil-stimulating activity.
J Immunol, 140 (1988), pp. 3534-3540
[41]
American Thoracic Society, European Respiratory Society.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
Am J Respir Crit Care Med, 165 (2002), pp. 277-304
[42]
A Xaubet, J Ancochea, R Blanquer, C Montero, F Morell, E Rodríguez Becerra, Grupo de Investigación en EnfermedadesPulmonares Intersticiales Difusas, et al.
Área de Técnicas y Trasplante. SEPAR. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.
Arch Bronconeumol, 39 (2003), pp. 580-600
[43]
M Serrano, M Molina-Molina, J Ramírez, M Sánchez, A Xaubet.
Fibrosis pulmonar intersticial centrada en las vías aéreas asociada a la inhalación de productos de limpieza.
Arch Bronconeumol, 42 (2006), pp. 557-559
[44]
A Serrano-Mollar, M Nacher, G Gay-Jordi, D Closa, A Xaubet, O Bulbena.
Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis.
Am J Respir Crit Care Med, 176 (2007), pp. 1261-1268
[45]
O Acosta.
Marcadores séricos en la fibrosis pulmonar idiopática. Implicación pronóstica.
Arch Bronconeumol, 42 (2006), pp. 377-379
[46]
N Kohno, Y Awaya, T Oyama, M Yamakido, M Akiyama, Y Inoue, et al.
KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease.
Am Rev Respir Dis, 148 (1993), pp. 637-642
[47]
MK Winkler, JL Fowlkes.
Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis?.
Am J Physiol Lung Cell Mol Physiol, 283 (2002), pp. L1-L11
[48]
M Suga, K Iyonaga, H Ichiyasu, N Saita, H Yamasaki, M Ando.
Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.
Eur Respir J, 14 (1999), pp. 376-382
[49]
H Takahashi, T Fujishima, H Koba, S Murakami, K Kurokawa, Y Shibuya, et al.
Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.
Am J Respir Crit Care Med, 162 (2000), pp. 1109-1114
[50]
H Ohnishi, A Yokoyama, K Kondo, H Hamada, M Abe, K Nishimura, et al.
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.
Am J Respir Crit Care Med, 165 (2002), pp. 378-381
[51]
M Nakayama, H Satoh, H Ishikawa, M Fujiwara, H Kamma, M Ohtsuka, et al.
Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases.
Chest, 123 (2003), pp. 2001-2006
[52]
PJ Sime, RA Marr, D Gauldie, Z Xing, BR Hewlett, FL Graham, et al.
Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts.
Am J Pathol, 153 (1998), pp. 825-832
[53]
A Xaubet, A Marín-Arguedas, S Lario, J Ancochea, F Morell, J Ruiz-Manzano, et al.
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 168 (2003), pp. 431-435
[54]
SJ Yong, A Adlakha, AH Limper.
Circulating transforming growth factor-beta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis.
Chest, 120 (2001), pp. 68-70
[55]
M Molina-Molina, S Lario, P Luburich, J Ramírez, MT Carrión, A Xaubet.
Determinación en plasma del factor transformador del crecimiento b1 en la fibrosis pulmonar idiopática.
Arch Bronconeumol, 42 (2006), pp. 380-383
[56]
M Molina-Molina, J Pereda, A Xaubet.
Modelos experimentales para el estudio de la fibrosis pulmonar: utilidad práctica actual y futura.
Arch Bronconeumol, 43 (2007), pp. 501-507
[57]
SH Phan, RS Thrall, PA Ward.
Bleomycin-induced pulmonary fibrosis in rats: biochemical demonstration of increased rate of collagen synthesis.
Am Rev Respir Dis, 121 (1980), pp. 501-506
[58]
F Chua, J Gauldie, GJ Laurent.
Pulmonary fibrosis: searching for model answers.
Am J Respir Cell Mol Biol, 33 (2005), pp. 9-13
[59]
JM Antonini, K Starks, JR Roberts, L Millecchia, HM Yang, KM Rao.
Changes in F-actin organization induced by hard metal particle exposure in rat pulmonary epithelial cells using laser scanning confocal microscopy.
In Vitr Mol Toxicol, 13 (2000), pp. 5-16
[60]
X Li, H Zhang, V Soledad-Conrad, J Zhuang, BD Uhal.
Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo.
Am J Physiol Lung Cell Mol Physiol, 284 (2003), pp. L501-L507
[61]
M Molina-Molina, A Serrano-Mollar, O Bulbena, L Fernández-Zabalegui, D Closa, A Marín-Arguedas, et al.
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.
Thorax, 61 (2006), pp. 604-610
[62]
CK Haston, M Wang, RE Dejournett, X Zhou, D Ni, X Gu, et al.
Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice.
Hum Mol Genet, 11 (2002), pp. 1855-1863
[63]
JW Card, WJ Racz, JF Brien, SB Margolin, TE Massey.
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.
Toxicol Sci, 75 (2003), pp. 169-180
[64]
PG Coin, AR Osornio-Vargas, VL Roggli, AR Brody.
Pulmonary fibrogenesis after three consecutive inhalation exposures to chrysotile asbestos.
Am J Respir Crit Care Med, 154 (1996), pp. 1511-1519
[65]
M Arras, J Louahed, V Simoen, V Barbarin, P Misson, S Van den Brûle, et al.
B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice.
Am J Respir Cell Mol Biol, 34 (2006), pp. 573-580
[66]
J Portnoy, T Pan, CA Dinarello, JM Shannon, JY Westcott, L Zhang, et al.
Alveolar type II cells inhibit fibroblast proliferation: role of IL1alpha.
Am J Physiol Lung Cell Mol Physiol, 290 (2006), pp. L307-L316
[67]
J Gea, E Barreiro.
Actualización en los mecanismos de disfunción muscular en la EPOC.
Arch Bronconeumol, 44 (2008), pp. 328-337
[68]
K Kontogianni, N Messini-Nikolaki, K Christou, K Gourgoulianis, S Tsilimigaki, SM Piperakis.
DNA damage and repair capacity in lymphocytes from obstructive sleep apnea patients.
Environ Mol Mutagen, 48 (2007), pp. 722-727
[69]
C Hernández, J Abreu, P Abreu, R Colino, A Jiménez.
Efectos del tratamiento con CPAP nasal en el estrés oxidativo en pacientes con síndrome de apnea del sueño.
Arch Bronconeumol, 42 (2006), pp. 125-129
[70]
K Christou, AN Moulas, C Pastaka, KI Gourgoulianis.
Antioxidant capacity in obstructive sleep apnea patients.
Sleep Med, 4 (2003), pp. 225-228
[71]
Christou K, Kostikas K, Pastaka C, Tanou K, Antoniadou I, Gourgoulianis KI. Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. Sleep Med. In press.
[72]
E Barreiro, A Nowinski, J Gea, P Sliwinski.
Oxidative stress in the external intercostal muscles of patients with obstructive sleep apnoea.
Thorax, 62 (2007), pp. 1095-1101
[73]
World Health Organization.
Global tuberculosis control: surveillance, planning, financing, WHO Report, (2004),
[74]
PJ Cardona, I Amat.
Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis.
Arch Bronconeumol, 42 (2006), pp. 25-32
[75]
PJ Cardona, E Julián, X Vallès, S Gordillo, M Muñoz, M Luquin, et al.
Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis.
Scand J Immunol, 55 (2002), pp. 639-645
[76]
PJ Cardona.
Vacunas terapéuticas contra la tuberculosis: un futuro brillante.
Arch Bronconeumol, 43 (2007), pp. 591-593
[77]
PJ Cardona, I Amat, S Gordillo, V Arcos, E Guirado, J Díaz, et al.
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Vaccine, 23 (2005), pp. 1393-1398
[79]
MA Marcos, MT Jiménez de Anta, JP de la Bellacasa, J González, E Martínez, E García, et al.
Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults.
Eur Respir J, 21 (2003), pp. 209-214
[80]
C Guerrero, CM Toldos, G Yagüe, C Ramírez, T Rodríguez, M Segovia.
Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine.
J Clin Microbiol, 42 (2004), pp. 467-468
[81]
J Domínguez, N Galí, L Matas, P Pedroso, A Hernández, E Padilla, et al.
Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 896-898
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
